Are Anti-Receptor-Binding Domain Antibodies Still a Relevant Proxy for Monitoring SARS-CoV-2 Neutralizing Activity in the Omicron Era?

Clin Chem. 2022 Jul 3;68(7):984-986. doi: 10.1093/clinchem/hvac085.

COVID SER Study Group:
Nicolas Guibert, Dulce Alfaiate, Amélie Massardier-Pilonchery, Virginie Pitiot, Florence Morfin-Sherpa, Bruno Lina, Cécile Barnel, Constance d'Aubarede, Vanessa Escuret, Laurence Josset, Hélène Lozano, Bouchra Mokdad, Fanny Joubert, Camille Mena

¹ Virology laboratory, Institute of Infectious Agents, Laboratory associated with the National Reference Centre for Respiratory Viruses, Hospices Civils of Lyon, F-69317 Lyon Cedex 04, France.
² CIRI- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308, ENS Lyon, Saint-Etienne University, Claude Bernard Lyon 1 University, F-69008 Lyon, France.
³ Department of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, 42270 Saint-Priest-en-Jarez, France.
⁴ Occupational Health and Medicine Department, Hospices civils of Lyon, F-69317 Lyon cedex 04, Lyon, France.

No abstract available

Publication types